Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Search Results to

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

PropertyValue
has major subject area list Dermatologic Agents; Dermatomyositis; Immunosuppressive Agents; Infliximab
information resource reference Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, Cabalar IV, Faghihi-Kashani S, Harris-Love MO, Plotz PH, Miller FW, Gourley M. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 06; 47(6):858-864.
label A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Search Criteria
  • Dermatomyositis Childhood Type

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)